ASIA-PACIFIC-SORAFENIB-(ORIENTAL)

NCT00492752 📎

Regimen

Experimental
sorafenib 400 mg BID
Control
placebo

Population

Advanced hepatocellular carcinoma in Asia-Pacific (predominantly HBV), Child-Pugh A, no prior systemic therapy

Key finding

mOS 6.5 vs 4.2 mo (HR 0.68, 95% CI 0.50-0.93, p=0.014); mTTP 2.8 vs 1.4 mo (HR 0.57, p=0.0005); **absolute OS shorter than SHARP (6.5 vs 10.7 mo)** due to Asia-Pacific HBV-dominant, later-stage cohort; etiology: HBV ~73% (vs ~19% in SHARP)

Source: PMID 19095497

Timeline